Clinical trials: Chronic Obstructive Pulmonary Disorder
- Condition Chronic Obstructive Pulmonary Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
GSK2269557 is being developed as an anti-inflammatory and anti-infective agent for the treatment of inflammatory airways diseases.
- Trial name
- NCT03189589
- Testing
- GSK2269557 500 µg, GSK2269557 750 µg
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
This trial in healthy subjects will assess PUR118's effect on attenuating ozone induced airway inflammation. This trial will establish the tolerability of PUR118 in healthy normal volunteers.
- Trial name
- NCT01690949
- Testing
- PUR118
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
COPD
Drug-drug Interaction Study of CHF5993 With Cimetidine
The purpose of this study is to evaluate the pharmacokinetic interaction when CHF5993 (pressurized metered-dose inhaler (pMDI) is administered with Cimetidine (probe inhibitor of the organic cation transport in the kidneys), by…
- Trial name
- NCT02287272
- Testing
- CHF 5993 pMDI, Cimetidine plus CHF5993 pMDI
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Study is Being Conducted in Healthy Volunteers
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and without a spacer device.
- Trial name
- NCT02934607
- Testing
- Symbicort pMDI with spacer device, Symbicort pMDI without spacer device
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, Pulmonary Disease, Chronic Obstructive
Relative Bioavailability of of Olodaterol and Ketoconazole
This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol
- Trial name
- NCT01153711
- Testing
- BI 1744, Ketoconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males
This will be an open label study conducted at one site. Six healthy male subjects will be enrolled to ensure at least four fully evaluable subjects.
- Trial name
- NCT00599612
- Testing
- GW856553
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone
A study to evaluate the effect of SB-656933-AAA on the body after a single dose in subjects who have been challenged with ozone.
- Trial name
- NCT00551811
- Testing
- SB-656933-AAA
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
Pharmacokinetics and Safety Study of PT010 in Healthy Subjects
This is a single-center, Phase I, healthy adult subject study with a randomized, double blind, three period, three-treatment, cross-over design.
- Trial name
- NCT02189304
- Testing
- PT010, PT009, Symbicort Turbohaler
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Cardiac Safety of Indacaterol
This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.
- Trial name
- NCT01263808
- Testing
- Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg
- Where
- United States
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol
The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug delivery characteristics comparable to the…
- Trial name
- NCT01540708
- Testing
- SERETIDE Rotacaps, SERETIDE Diskus
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients
There are three elements to this study: Part A: Single dose escalation in healthy subjects. 6 dose levels of QAK423 are planned in healthy volunteers. Part B: Single dose escalation in patients with mild/moderate COPD.
- Trial name
- NCT01197287
- Testing
- QAK423A
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants
This study will compare two formulations of the investigational medicine GSK3862995B in healthy adults. The study aims to assess how the body absorbs and processes the medicine, and to evaluate its safety and tolerability.
- Trial name
- NCT07789899
- Testing
- GSK3862995B
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
The Effect of Volitional Pursed-lips Breathing
Simulation of pursed-lips breathing by defined stenoses in pulmonary function diagnostics to quantify the effect of the pursed-lips breathing
- Trial name
- PLB (NCT04663698)
- Testing
- Baseline, MESH-Resistor 5, MESH-Resistor 10
- Where
- Germany
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Karl Josef Franke, PD DR med
Chronic Obstructive Pulmonary Disease
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
The objective of this study is to investigate the effect of the interaction of Erythromycin (CYP3A4/5 moderate inhibitor) on the pharmacokinetic of CHF6001 (CYP3A4/5 substrate) in Healthy Volunteers.
- Trial name
- NCT06395610
- Testing
- CHF6001 DPI, Erythromycin
- Where
- Bulgaria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways
AZD2115 Single Ascending Dose Study
AZD2115 Single Ascending Dose Study
- Trial name
- NCT01283984
- Testing
- AZD2115
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
AZD8871 is a new chemical entity possessing long-acting effect in a single molecule which presents a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an…
- Trial name
- NCT02814656
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease COPD
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
This is a randomized, single-blind, placebo-controlled, sequential-group study to assess the safety and tolerability as well as how the drug (AZD7594) affects the body (pharmacodynamics [PD]) and how the body affects the drug…
- Trial name
- NCT02645253
- Testing
- AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug
This single and repeat increasing dose study will collect information on safety, tolerability and drug levels in the body of the CCI15106 inhalation powder.
- Trial name
- NCT03235726
- Testing
- CCI15106
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline